Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Biosimilars Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (Europe)" report has been added to ResearchAndMarkets.com's offering.
The Europe biosimilars market is projected to grow from US$ 15.32 Bn in 2025 to US$ 43.4 Bn by 2032, reflecting a CAGR of 16.03%
The competitive Analysis is becoming increasingly dynamic with the involvement of major pharmaceutical companies and specialized biosimilar developers. The Europe biosimilars market is poised for substantial growth, driven by increasing demand for cost-effective therapeutic solutions, robust regulatory frameworks, and expanding awareness among healthcare providers and patients. With a growing shift toward value-based healthcare models and heightened pressure on healthcare budgets, biosimilars are becoming a pivotal component in the region's therapeutic Analysis.
Europe's biosimilars market is evolving rapidly, supported by favorable policies and a proactive stance on pharmaceutical innovation. Regulatory bodies such as the European Medicines Agency (EMA) have streamlined approval processes for biosimilars, enabling faster market entry while maintaining strict standards for safety, efficacy, and quality.
The growing demand for biosimilar drugs is reshaping healthcare delivery across Europe. Biosimilars are being widely adopted for their ability to offer high-quality, affordable alternatives to expensive biologics, especially in chronic and life-threatening disease treatments such as oncology, rheumatology, and immunology.
A cumulative savings of over €50 billion has been achieved in Europe since the introduction of biosimilars, with significant savings realized in 2023 alone. This demonstrates their growing role in ensuring sustainability in national healthcare systems.
Market Drivers
One of the primary growth drivers is the increasing number of patent expiries of originator biologics. The expiration of exclusivity rights opens the market to biosimilars, which can then be introduced at more affordable prices, leading to higher uptake among healthcare providers and patients.
Cost containment is a top priority for many European nations, and biosimilars play a critical role in achieving this goal. Governments and healthcare institutions are promoting biosimilars through price incentives, reimbursement policies, and prescription quotas to encourage their adoption.
Wider reimbursement coverage and pricing approvals across Europe also contribute to market expansion. National healthcare systems are increasingly including biosimilars in public programs, improving affordability and accessibility.
Business Opportunities
The Europe biosimilars market presents strong opportunities for manufacturers in multiple therapeutic areas. A particularly promising avenue is the switch from reference biologics to biosimilars. As physician confidence grows and real-world data continues to support biosimilar efficacy, switching programs are gaining traction, helping to reduce healthcare costs significantly.
Additionally, the expansion of biosimilars into non-oncology therapeutic areas such as autoimmune diseases, diabetes, and inflammatory disorders is expected to drive further market growth. These segments present vast patient populations in need of long-term treatment, making affordability a key concern that biosimilars can address.
With an estimated loss of exclusivity for approximately 10 biological medicines between 2030 and 2032, worth nearly €30 billion, manufacturers have a golden opportunity to capitalize on these gaps by introducing new biosimilars.
Challenges and Restraints
Despite the strong market momentum, certain challenges persist. Intellectual property and patent litigation continue to delay market entry for many biosimilars. Complex patent portfolios and "evergreening" strategies by originator companies often lead to legal battles that deter smaller biosimilar manufacturers.
Additionally, adoption rates remain inconsistent across European countries due to cultural, regulatory, and educational barriers. Physicians in certain regions remain hesitant to prescribe biosimilars despite comparable safety and efficacy, often due to lack of familiarity or minimal pricing differences.
Market Overview
- Market Definitions and Segmentations
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Value Chain Analysis
- Porter's Five Forces Analysis
- COVID-19 Impact Analysis
- Supply
- Demand
- Impact of Ukraine-Russia Conflict
- Economic Overview
- World Economic Projections
- PESTLE Analysis
Key Players
- Fresenius Kabi
- Biogen Inc.
- Celltrion, Inc.
- Pfizer Inc.
- Amgen Inc.
- Samsung Bioepis Co., Ltd.
- Biocon
- Viatris (Mylan Pharmaceuticals Inc.)
- Coherus BioSciences, Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Eli Lilly and Company
- Bio-Thera Solutions, Ltd.
Europe Biosimilars Market Segmentation
By Drug:
- Adalimumab
- Bevacizumab
- Trastuzumab
- Rituximab
- Infliximab
- Etanercept
- Epoetin alfa
- Filgrastim
- Other Biosimilars
By Drug Class:
- Antirheumatics
- TNF Alfa Inhibitors
- VEGF/VEGFR Inhibitors
- HER2 Inhibitors
- Selective Immunosuppressants
- Interleukin Inhibitors
By Indication:
- Oncology Diseases
- Autoimmune Diseases
- Skin Disorders
- Inflammatory Bowel Disease (IBD)
- Rare Diseases
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- Germany
- France
- U.K.
- Italy
- Spain
- Russia
- Rest of Europe
For more information about this report visit https://www.researchandmarkets.com/r/8f4avg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
